BioGX Expands Xfree Respiratory PCR With COVID-19/Flu A/Flu B Multiplex, Group A Streptococcus, Mycoplasma Pneumoniae

07 Sep 2023
www.biospace.com
Diagnostic Reagents
BIRMINGHAM, AL / ACCESSWIRE / September 7, 2023 / BioGX, a global provider of molecular diagnostic solutions, announces the availability of three new Xfree™ Direct-Sample-to-Answer PCR multiplexes for the detection of Group A Streptococcus, Mycoplasma pneumoniae and Flu A, Flu B, COVID-19 N1/RdRp. Xfree Flu A, Flu B, COVID-19 and Group A Streptococcus were previously CE-IVD marked while Mycoplasma pneumoniae is available as research use only. Laboratories can request custom manufactured formats for high-throughput use that may be validated for their intended use on a variety of real-time PCR platforms including, the BioGX pixl™, Applied Biosystems 7500, ThermoFisher QuantStudio and Bio-Rad CFX Touch. "Our Xfree chemistry has proven to be highly robust in our FDA-EUA COVID-19 test. We are excited to offer expanded respiratory panels to equip our customers with cost-effective, rapid PCR workflows," said Shahin Iqbal, Ph.D., President & COO of BioGX. Xfree technology provides a complete lyophilized test in a single tube in the trusted BioGX Sample-Ready™ format for extraction-free, direct sample addition real-time PCR testing. This format eliminates pre-treatment and nucleic acid extraction steps, enabling labs with a simple Sample-to-Answer workflow. The test can be shipped anywhere in the world without refrigeration. To request more information on BioGX Xfree products and our other testing solutions, please contact sales@biogx.com. Contact Information Bill Standwill Head of Marketing marketing@biogx.com (205) 250-8055 SOURCE: BioGX View source version on accesswire.com:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.